Standard

Peptide-based targeting of connexins and pannexins for therapeutic purposes. / Caufriez, Anne; Böck, Denise; Martineau, Charlotte; Ballet, Steven; Vinken, Mathieu.

In: Expert Opinion on Drug Discovery, Vol. 15, No. 10, 10, 01.10.2020, p. 1213-1222.

Research output: Contribution to journalArticle

Harvard

Caufriez, A, Böck, D, Martineau, C, Ballet, S & Vinken, M 2020, 'Peptide-based targeting of connexins and pannexins for therapeutic purposes', Expert Opinion on Drug Discovery, vol. 15, no. 10, 10, pp. 1213-1222.

APA

Caufriez, A., Böck, D., Martineau, C., Ballet, S., & Vinken, M. (2020). Peptide-based targeting of connexins and pannexins for therapeutic purposes. Expert Opinion on Drug Discovery, 15(10), 1213-1222. [10].

Vancouver

Caufriez A, Böck D, Martineau C, Ballet S, Vinken M. Peptide-based targeting of connexins and pannexins for therapeutic purposes. Expert Opinion on Drug Discovery. 2020 Oct 1;15(10):1213-1222. 10.

Author

Caufriez, Anne ; Böck, Denise ; Martineau, Charlotte ; Ballet, Steven ; Vinken, Mathieu. / Peptide-based targeting of connexins and pannexins for therapeutic purposes. In: Expert Opinion on Drug Discovery. 2020 ; Vol. 15, No. 10. pp. 1213-1222.

BibTeX

@article{9ef4787b2cc046e3a28a85298e8d9a97,
title = "Peptide-based targeting of connexins and pannexins for therapeutic purposes",
abstract = "Introduction: Connexin and pannexin (hemi)channels play an important role in paracrine and autocrine signaling pathways. The opening of these cellular pores is linked to a wide range of diseases. Therefore, pharmacological closing of connexin and pannexin (hemi)channels seems a promising therapeutic strategy. However, the currently available inhibitors cope with recurring problems concerning selectivity, specificity, stability and/or solubility. Areas covered: A number of peptides that mimic specific regions in the native sequence of connexins and pannexins have the potential to overcome some of these hurdles. In this paper, an overview is provided on these peptide-based inhibitors of connexin and pannexin (hemi)channels for therapeutic purposes. The authors also provide the reader with their expert perspectives on the future of these peptide-based inhibitors. Expert opinion: Peptide mimetics can become valuable tools in the treatment of connexin-related and pannexin-related diseases. This can be made possible provided that available peptides are optimized, and new peptide mimetics are designed based on knowledge of the mechanisms underlying the gating control of connexin and pannexin (hemi)channels.",
author = "Anne Caufriez and Denise B{\"o}ck and Charlotte Martineau and Steven Ballet and Mathieu Vinken",
year = "2020",
month = "10",
day = "1",
language = "English",
volume = "15",
pages = "1213--1222",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "10",

}

RIS

TY - JOUR

T1 - Peptide-based targeting of connexins and pannexins for therapeutic purposes

AU - Caufriez, Anne

AU - Böck, Denise

AU - Martineau, Charlotte

AU - Ballet, Steven

AU - Vinken, Mathieu

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Introduction: Connexin and pannexin (hemi)channels play an important role in paracrine and autocrine signaling pathways. The opening of these cellular pores is linked to a wide range of diseases. Therefore, pharmacological closing of connexin and pannexin (hemi)channels seems a promising therapeutic strategy. However, the currently available inhibitors cope with recurring problems concerning selectivity, specificity, stability and/or solubility. Areas covered: A number of peptides that mimic specific regions in the native sequence of connexins and pannexins have the potential to overcome some of these hurdles. In this paper, an overview is provided on these peptide-based inhibitors of connexin and pannexin (hemi)channels for therapeutic purposes. The authors also provide the reader with their expert perspectives on the future of these peptide-based inhibitors. Expert opinion: Peptide mimetics can become valuable tools in the treatment of connexin-related and pannexin-related diseases. This can be made possible provided that available peptides are optimized, and new peptide mimetics are designed based on knowledge of the mechanisms underlying the gating control of connexin and pannexin (hemi)channels.

AB - Introduction: Connexin and pannexin (hemi)channels play an important role in paracrine and autocrine signaling pathways. The opening of these cellular pores is linked to a wide range of diseases. Therefore, pharmacological closing of connexin and pannexin (hemi)channels seems a promising therapeutic strategy. However, the currently available inhibitors cope with recurring problems concerning selectivity, specificity, stability and/or solubility. Areas covered: A number of peptides that mimic specific regions in the native sequence of connexins and pannexins have the potential to overcome some of these hurdles. In this paper, an overview is provided on these peptide-based inhibitors of connexin and pannexin (hemi)channels for therapeutic purposes. The authors also provide the reader with their expert perspectives on the future of these peptide-based inhibitors. Expert opinion: Peptide mimetics can become valuable tools in the treatment of connexin-related and pannexin-related diseases. This can be made possible provided that available peptides are optimized, and new peptide mimetics are designed based on knowledge of the mechanisms underlying the gating control of connexin and pannexin (hemi)channels.

M3 - Article

VL - 15

SP - 1213

EP - 1222

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 10

M1 - 10

ER -

ID: 51998403